Rekombinanter SARS-CoV-2 Spike S1 Antikörper

Produktnummer ABIN7566484

Dieses Maus Monoklonal-Antikörper erkennt spezifisch SARS-CoV-2 Spike S1 in ELISA, WB und ICC. Er zeigt eine Reaktivität gegenüber SARS Coronavirus-2 (SARS-CoV-2).

Kurzübersicht für Rekombinanter SARS-CoV-2 Spike S1 Antikörper (ABIN7566484)

Target: SARS-CoV-2 Spike S1

Antikörpertyp: Recombinant Antibody

Reaktivität: SARS Coronavirus-2 (SARS-CoV-2)

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser SARS-CoV-2 Spike S1 Antikörper ist unkonjugiert

Applikation: ELISA, Western Blotting (WB), Immunocytochemistry (ICC)

Klon: AB66-6-C10

Produktdetails anti-SARS-CoV-2 Spike S1 Antikörper

Verwendungszweck: anti-SARS-CoV-2 Spike Protein S1 (SD2), mAb (rec.) (AB66-6-C10)

Produktmerkmale:

Recombinant Antibody. Recognizes the SARS-CoV-2 S1 (SD2 subdomain). Does not cross-react with HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-HKU1, MERS-CoV or SARS-CoV. Applications: ELISA, ICC, WB. Clone: AB66-6-C10. Isotype: Mouse IgG2a. Formulation: Liquid. In PBS. Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S protein plays a key role in viral infection and pathogenesis. The S1 subunit contains the N-terminal domain (NTD), a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells, and 2 structurally conserved subdomains (SD1 and SD2), whereas S2 harbors heptad repeat 1 (HR1) and HR2. The RBD domain first binds its receptor to form an RBD/ACE2 complex. This triggers conformational changes in the S protein, leading to membrane fusion mediated via HR1 and HR2 and consequently in viral entry into target cells. Antibodies targeting various regions of S protein have different mechanisms in inhibiting SARS-CoV-2 infection. For example, NTD-targeting antibodies bind the NTD to form an NTD/mAb complex, thereby preventing conformational changes in the S protein and blocking membrane fusion and viral entry. RBD-targeting antibodies form RBD/mAb or RBD/Nb complexes that inhibit binding of the RBD to ACE2, thereby preventing entry of SARS-CoV-2 into target cells.

Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S protein plays a key role in viral infection and pathogenesis. The S1 subunit contains the N-terminal domain (NTD), a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells, and 2 structurally conserved subdomains (SD1 and SD2), whereas S2 harbors heptad repeat 1 (HR1) and HR2. The RBD domain first binds its receptor to form an RBD/ACE2 complex. This triggers conformational changes in the S protein, leading to membrane fusion mediated via HR1 and HR2 and consequently in viral entry into target cells. Antibodies targeting various regions of S protein have different mechanisms in inhibiting SARS-CoV-2 infection. For example, NTD-targeting antibodies bind the NTD to form an NTD/mAb complex, thereby preventing conformational changes in the S protein and blocking membrane fusion and viral entry. RBD-targeting antibodies form RBD/mAb or RBD/Nb complexes that inhibit binding of the RBD to ACE2, thereby preventing entry of SARS-CoV-2 into target cells.

Aufreinigung: Puified

Reinheit: >95 % (SDS-PAGE)

Immunogen: Recombinant SARS-CoV-2 S1 Protein (aa 14-685) containing a C-terminal human Fc-tag.

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: In PBS.

Handhabung: After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.Please handle under sterile conditions to avoid contamination.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung:

Stable for at least 1 year after receipt when stored at -20°C.

Stable for at least 3 months after receipt when stored at +4°C.

Details zu SARS-CoV-2 Spike S1

Target: SARS-CoV-2 Spike S1

Andere Bezeichnung: SARS-CoV-2 Spike Protein S1